Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)
| Autor: | Michael D. Huband, Cecilia G Carvalhaes, Robert K. Flamm, Harald H Reinhart, Helio S. Sader |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
China
Staphylococcus aureus Meticillin Enterococcus faecium Taiwan Microbial Sensitivity Tests medicine.disease_cause Microbiology Epidemiology and Surveillance 03 medical and health sciences 0302 clinical medicine Enterobacteriaceae Streptococcus pneumoniae medicine Humans Pharmacology (medical) 030212 general & internal medicine Pharmacology 0303 health sciences biology 030306 microbiology Soft Tissue Infections Broth microdilution Bacterial Infections biology.organism_classification Haemophilus influenzae Anti-Bacterial Agents Penicillin Community-Acquired Infections Infectious Diseases Viridans streptococci Tetracyclines Vancomycin Hong Kong Staphylococcal Skin Infections Enterobacter cloacae medicine.drug |
| Popis: | Omadacycline is a derivative of minocycline and the first agent of the aminomethylcycline class. A total of 3,282 organisms (1 per patient) were consecutively collected from patients hospitalized in China (including Hong Kong) and Taiwan. Susceptibility testing was performed by broth microdilution methods in a central laboratory (JMI Laboratories). The collection included Gram-positive and Gram-negative organisms from patients with pneumonia, bloodstream, skin, community-acquired respiratory, and other infections. Omadacycline was very potent against Staphylococcus aureus (n = 689; MIC(50/90), 0.12/0.25 mg/liter), including methicillin-resistant Staphylococcus aureus (MRSA; n = 299; MIC(50/90), 0.12/0.5 mg/liter), and had similar activity across geographic regions. Omadacycline was very active against Streptococcus pneumoniae (highest MIC, 0.25 mg/liter), β-hemolytic streptococci (highest MIC, 1 mg/liter), viridans group streptococci (highest MIC, 0.25 mg/liter), and Enterococcus spp. (highest MIC, 0.5 mg/liter) from all geographic regions. Overall, 53.8% of S. pneumoniae isolates were penicillin resistant (penicillin MIC, ≥2 mg/liter) and 10.7% of enterococci (21.2% among E. faecium isolates) were vancomycin resistant. Omadacycline was active against Haemophilus influenzae (MIC(50/90), 0.5/1 mg/liter) regardless of β-lactamase production and was active against Moraxella catarrhalis (MIC(50/90), ≤0.12/0.25 mg/liter). Against Enterobacteriaceae, omadacycline was most active against Escherichia coli (MIC(50/90), 1/2 mg/liter), Klebsiella oxytoca (MIC(50/90), 1/4 mg/liter), and Enterobacter cloacae (MIC(50/90), 2/4 mg/liter). Omadacycline had potent in vitro activity against Gram-positive and Gram-negative pathogens isolated from China and Taiwan and retained activity against problem pathogens, such as MRSA, vancomycin-resistant enterococci (VRE), penicillin-resistant S. pneumoniae (PRSPN), and extended-spectrum β-lactamase-producing E. coli. The observed MIC profile in Chinese isolates was very similar to that seen in the U.S. and European surveillance studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|